Corporate Presentation June 2025 JENNIFER Living with SCA3 JENNIFER Living with SCA3 Participant in the Troriluzole Clinical Study © 2025 Biohaven, Ltd. All rights reserved. Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about Biohaven Ltd. (the "Company") and our planned and ongoing trials for our troriluzole, taldefgrobep alfa, BHV-7000, BHV-2100, BHV-8000, BHV-1300, BHV-1400, ...

NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Biohaven Ltd.  (“Biohaven” or the “Company”) (NYSE: BHVN).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Biohaven and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On May 14, 2025, ...

Volatile biotech stock Biohaven (BHVN -19.41%) is prone to sharp movements both up and down. On Thursday, it had one of its down days, with its share price eroding by almost 20% on a development with a top regulator. That was on a day when stocks generally did well, as indicated by the S&P 500 (^GSPC 0.41%) landing in positive territory with a 0.4% rise. A regulatory extensionAfter market close on Wednesday, Biohaven divulged that the U.S. Food and Drug Administration's (FDA) Division of Neurology 1 is exte ...

Core Viewpoint - Troriluzole is a potential first and only FDA-approved treatment for Spinocerebellar Ataxia (SCA), a rare and life-threatening neurodegenerative disease, with the FDA extending the review period for its new drug application [2][3]. Group 1: Troriluzole and FDA Review - The FDA has extended the PDUFA date for the new drug application of Troriluzole by three months to allow for a full review of recent submissions [2]. - The FDA has not raised any new concerns regarding the application, and a meeting with an advisory committee is planned [2][4]. - Troriluzole has received Fast-Track, Orphan Drug Designation, and Priority Review from the FDA, indicating its potential to significantly improve treatment options for SCA [3][4]. Group 2: Impact of Troriluzole - Clinical data suggests that Troriluzole can slow disease progression by 50-70% as measured by the f-SARA scale and reduce the risk of falls [4]. - SCA affects approximately 15,000 people in the United States and 24,000 in Europe and the UK, leading to significant morbidity and no current approved therapies [5]. Group 3: Mechanism of Action - Troriluzole is a third-generation novel prodrug that modulates glutamate levels, addressing glutamate deregulation associated with neurodegeneration in SCA patients [6]. - The drug increases glutamate uptake from the synapse, enhancing the function of excitatory amino acid transporters on glial cells [6]. Group 4: Company Overview - Biohaven is focused on developing life-changing treatments in key therapeutic areas, including neuroscience, and has a diverse portfolio of drug candidates [7].

Shares of Biohaven (BHVN 5.04%) are surging on Monday. The company's stock was up about 8% as of midday trading and had climbed as much as 10% earlier in the day. The move comes as the S&P 500 traded mixed and the Nasdaq Composite drifted slightly higher.Shares of the clinical-stage biopharmaceutical company were rising after Biohaven announced a $600 million non-dilutive financing deal with Oberland Capital.A big cash infusionBiohaven revealed it has secured up to $600 million from the investment firm Ober ...

On Friday's news that Biohaven (BHVN -15.34%) withdrew its application for a top investigational drug from an important regulator, investors aggressively traded out of the stock. The clinical-stage biotech was one of the biggest decliners in its industry, exiting Friday with a share price decline of over 15%. This was during a session that was essentially bullish; the S&P 500 index closed 0.6% higher. Strategic withdrawalThat news came not from Biohaven itself, but from the European Medicines Agency (EMA, t ...